Pfizer's Weight-Loss Data Just Upends Investor Bets
Pfizer is stepping into a high-stakes arena long led by Lilly and Novo Nordisk. This article analyzes what pfizer's w...
Pharma Stocks
Pharma Stocks collects four articles on big pharma movers, from Novo Nordisk to Merck, highlighting value, growth angles, and dividend potential to help smarter investing.
48 articles
Prediction: Lilly Will Reach $1,200 in 2026 — Investment Thesis
Eli Lilly’s GLP-1 drugs are redefining growth in obesity and diabetes treatment. This article lays out why the stock ...
Reasons Lilly Remains a Buy: 3 Strong Drivers for Investors
Investors are eyeing Lilly for its resilient growth, strong pipeline, and shareholder-friendly strategy. This piece b...
Forget Zepbound: Lilly's Next Stock Signal for Investors
Lilly’s Zepbound has shaken up the obesity-drug market, but the real upside could come from its next-generation candi...
Bristol Myers Pfizer: Which High Yield Stock Wins Now?
Two pharma giants compete for your portfolio's income. This guide weighs yields, safety, and long-term risks to answe...
Johnson Johnson Hopes Dethrone AbbVie’s Growth Driver
Two pharma giants are wighting for a leadership position in immunology. This piece explains why Johnson Johnson hopes...
Novo Nordisk Beating Lilly in Obesity Pill Market: What It Means for Investors
Novo Nordisk is gaining ground on Lilly in the obesity pill market. This article breaks down the drivers, the competi...
President Trump's Drug Pricing Policy and Pharma Stocks
Policy shifts around president trump's drug pricing could squeeze pharma profits and shift stock dynamics. This guide...
Lilly Just Huge Vote: Morgan Stanley Bets on Mounjaro
A major investment bank just signaled a powerful vote of confidence in Lilly's GLP-1 strategy. This article breaks do...
Lilly Just Made Game-Changing Moves in Weight-Loss Space
A big strategic shift from Lilly could redefine how investors view weight-loss drugs. This article breaks down what h...
Best Weight Loss Drug Stocks to Buy in 2026: Top Picks
As GLP-1 therapies reshape obesity treatment, investors eye the best weight loss drug stock bets for 2026. This guide...
Pfizer Just Locked Next Growth Path: What Investors Should Know
Pfizer has reset its growth trajectory with big bets on Seagen and a future GLP-1 drug. This analysis breaks down wha...